Samsung Biologics Expands U.S. Footprint with GSK Facility Acquisition
Event summary
- Samsung Biologics completed the acquisition of GSK's Rockville, Maryland facility on March 31, 2026.
- The facility adds 60,000 liters of drug substance capacity, bringing Samsung's total global capacity to 845,000 liters.
- The site will continue supplying products to GSK while transitioning to serve additional contract manufacturing needs.
- Samsung plans further investments to expand the site's capacity and upgrade technologies.
- The acquisition marks Samsung's first U.S. manufacturing presence, diversifying its global network.
The big picture
This acquisition solidifies Samsung Biologics' position as a major player in the contract development and manufacturing space, particularly in the U.S. The move comes amid increasing demand for resilient global supply chains in biopharmaceuticals, as companies seek to mitigate geopolitical and logistical risks. The addition of the Rockville facility also positions Samsung to better serve its existing and potential clients in North America, a key market for biologics production.
What we're watching
- Integration Challenges
- How Samsung Biologics will integrate the Rockville site's operations and personnel into its existing network.
- Capacity Utilization
- The pace at which Samsung fills the new capacity with additional contract manufacturing clients.
- Technological Upgrades
- Whether the planned investments in the Rockville site will enhance its competitiveness in the U.S. market.
Related topics